MMORE for Multiple Myeloma Research Fund

The MMORE for Multiple Myeloma Research Fund was established by the efforts of Multiple Myeloma Opportunities for Research & Education (MMORE) — a 501(c)(3) nonprofit corporation dedicated to raising awareness and raising funds through fun and inspiring community events.

MMORE’s mission is to support multiple myeloma research to discover new life-prolonging treatments, improve quality of life for myeloma patients and ultimately find a cure for all multiple myeloma patients.

MMORE recently announced that they have reached their initial $1 million goal to support multiple myeloma research at the OSUCCC – James. But the work is not done. Every donation, big and small, comes together to support our mission of finding a cure for multiple myeloma.

MMORE Fund at Work

The multiple myeloma team at the OSUCCC – James has made incredible advances in multiple myeloma research through the efforts of MMORE and donations to the MMORE Fund, including:

  • MMORE dollars were spent to research ways to change the interaction between natural killer cells and myeloma cells, focusing on a novel antibody to help stimulate the body’s immune system to attack myeloma cells.
  • MMORE funds purchased the cytokine bead array system to analyze multiple signaling pathways in a tumor cell or immune cell at once, rather than one at a time as with older technology. This new technology allows us to see the “forest” rather than individual “trees” (that is, to see the effect of a drug on the entire cell and learn both how the drug works and how potential resistance is acquired to the treatment).
  • MMORE dollars helped developed three new strategies to enhance the immune system’s ability to recognize and kill multiple myeloma cells. This information has been used to provide preliminary data needed to fund a larger research effort.
  • MMORE dollars helped develop resources here at the OSUCCC – James and at collaborating organizations that target and kill myeloma cells. This area of research is in its infancy, but Ohio State has shown its ability to push this type of research onward. AR-42 was originally synthesized in the College of Pharmacy and, after years of testing, was administered in a first-in-humans study in June 2010 to patients with relapsed myeloma, lymphoma and chronic lymphocytic leukemia.
  • MMORE dollars are funding a myeloma data coordinator for three years to track all myeloma patients diagnosed at The Ohio State University. Additionally, through an IRB-approved collaboration with the Ohio Department of Health, this data registry will include all myeloma patients living in the state of Ohio to track myeloma patient treatments, survival and patient-reported outcomes. The data coordinator will encourage patients to participate in studies that freeze blood and bone marrow for future laboratory experiments, and also to participate in clinical trials studying potentially more effective drugs with fewer side effects.
  • MMORE-funded research at the OSUCCC – James has been published in scientific peer-reviewed publications.
  • MMORE has funded 12 current laboratory research projects, including a study of myelomagenesis — how myeloma starts in the first place.
  • Seed money from MMORE has allowed researchers at the OSUCCC – James to move research through the beginning phases of promising discoveries and become highly eligible for millions of dollars in funding from other sources.